Welcome to our dedicated page for Rafael Holdings SEC filings (Ticker: RFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rafael Holdings, Inc. filings document regulatory disclosures for a biotechnology company with Class B common stock listed on the New York Stock Exchange. The company’s reports include Form 8-K earnings releases, Regulation FD disclosures, clinical and intellectual-property updates tied to Cyclo Therapeutics, and material-event reporting related to its pharmaceutical development activities.
Proxy and meeting filings describe board elections, auditor ratification, equity incentive plan matters, committee governance and shareholder voting results. Securities-related filings cover Rafael’s Class B common stock, warrants to purchase Class B common stock, warrant exchange matters connected to the Cyclo Therapeutics merger, and Form 25 listing and registration notices for the warrant class.
Rafael Holdings (RFL) Form 4 filing – CFO David Polinsky reported a routine tax-withholding transaction on 06/21/2025. The company withheld 2,347 Class B common shares, valued at $1.595 per share, to cover statutory taxes triggered by the vesting of restricted stock units. The filing is coded “F,” confirming the shares were not sold in the open market but surrendered to the issuer. Following the transaction, the CFO continues to beneficially own 268,075 Class B shares, comprising 76,882 shares held outright, 69,943 vested restricted shares, and 121,250 unvested restricted shares that will vest in scheduled tranches through 01/13/2029. No new shares were acquired and no open-market sale was executed; the transaction has no direct cash impact and does not signal a change in insider sentiment. The filing maintains broad insider alignment, as the CFO retains a meaningful equity stake worth roughly $0.43 million at the reported price. Overall, the Form 4 appears administratively routine with negligible impact on the company’s capital structure or market perception.